.png)
.jpg "Oliver Liesenfeld, MS photo")
Chief Medical Officer
Inflammatix Inc
Burlingame, California, United States
Oliver Liesenfeld, MD, has over 25 years of industry and academic experience in the diagnostics field, with a focus on molecular diagnostics and infectious diseases. He heads the Clinical Affairs department at Inflammatix in support of clinical trial design and conduct. The Clinical Affairs department also supports product development and product management activities.
As Chief Medical Officer at Roche Molecular Diagnostics, he built a state-of-the-art medical department and led the company’s clinical science, medical affairs, clinical operations and biometrics functions. His team designed and executed numerous clinical trials to support regulatory approvals and commercialization of the company’s broad product portfolio, including the LightCycler® SeptiFast test for use in sepsis diagnosis.
Dr. Liesenfeld previously served as associate professor of Medical Microbiology and Infection Immunology at the Charite Medical School in Berlin, Germany, where his research focused on the immune response to infections. He holds an MD and a doctoral (Dr. med) degree from the Free University of Berlin, Germany and completed his residency in medical microbiology and infection epidemiology at the Charite Medical School, Berlin. He also completed a postdoctoral fellowship in the Division of Infectious Diseases and Geographic Medicine at Stanford University. Dr. Liesenfeld has authored more than 170 articles in peer-reviewed journals and more than 30 book chapters.